Selection of patients with breast cancer for routine follow-up bone scans

Coleman, RE; Fogelman, Ignac; Habibollahi, F.; North, W. R. S.; Rubens, Robert

doi:10.1016/s0936-6555(05)80995-1

Cited by 14 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same sentiment is echoed in the Invited Commentary by Karthikeyan and Park. 2 If we look at the lead time gained by radiographic early detection, as shown in previously conducted studies, 3,4 compared with symptomatic recurrence, it is around 6 months. A clinical lead time of more than 6 months was also seen in a randomized clinical trial comparing intensive vs clinical follow-up of patients with breast cancer after primary treatment.…”

Section: Clinical Benefit Of Circulating Tumor Dna Analysis In Early-...mentioning

confidence: 90%

“…Therefore, AE estimation in clinical trials may include symptoms that predate trial entry. This raises concern that the cumulative incidence of patientreported AEs may be high, particularly if preexisting symptoms related to other causes (eg, comorbidities, prior treatment) are attributed to study drugs.Just as patients are better positioned to detect symptomatic AEs during a trial, [3][4][5] we hypothesized that they are also better at reporting baseline symptoms. As such, we anticipated that patient reporting would facilitate better understanding of pretrial symptoms.…”

mentioning

confidence: 99%

“…Just as patients are better positioned to detect symptomatic AEs during a trial, [3][4][5] we hypothesized that they are also better at reporting baseline symptoms. As such, we anticipated that patient reporting would facilitate better understanding of pretrial symptoms.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

et al. 2020

View full text Add to dashboard Cite

Many patients enter cancer clinical trials with baseline symptoms. 1 Notably, the current clinician reporting mechanism for symptomatic adverse events (AEs) via the Common Terminology Criteria for Adverse Events (CTCAE) 2 does not formally distinguish between symptoms present at baseline vs those that develop during a trial. Therefore, AE estimation in clinical trials may include symptoms that predate trial entry. This raises concern that the cumulative incidence of patientreported AEs may be high, particularly if preexisting symptoms related to other causes (eg, comorbidities, prior treatment) are attributed to study drugs.Just as patients are better positioned to detect symptomatic AEs during a trial, [3][4][5] we hypothesized that they are also better at reporting baseline symptoms. As such, we anticipated that patient reporting would facilitate better understanding of pretrial symptoms. Moreover, if baseline symp-tom information were available, we might be able to adjust AE analyses to remove preexisting symptoms from tabulations, thereby enabling a focus on symptomatic AEs that are incident during the clinical trial.

show abstract

Section: Clinical Benefit Of Circulating Tumor Dna Analysis In Early-...mentioning

confidence: 90%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The role of imaging for detection of metastatic disease during follow‐up of patients with Stage I–III breast carcinoma increasingly has been called into question during the past decade 16, 24–26. At one time, bone scintigraphy was commonly used as part of routine follow‐up during the first several years after diagnosis of breast carcinoma, but the absence of a proven clinical benefit for early identification of asymptomatic metastatic disease has resulted in the discontinuation of this practice 24, 27–32.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma

Jacobson¹,

Shapiro²,

Abbeele³

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND To gain insight into the factors that contribute to the more favorable prognosis associated with recurrence limited to bone in patients with breast carcinoma, the authors analyzed the number of sites of initial involvement identified on radionuclide bone scans in relation to long term outcome. METHODS Records of 641 patients with clinical Stage I–III breast carcinoma that originally was diagnosed in 1974–1985 were reviewed. During follow‐up, 295 patients (46%) experienced distant recurrence, including 116 with bone as the sole initial site of metastatic disease. Radionuclide bone scans identified the initial site(s) of recurrence in 113 of these latter 116 patients, and these studies were categorized by the number of skeletal lesions subsequently confirmed as metastases (1, 2, or ≥ 3). Survival from time of recurrence and time of original diagnosis was analyzed using Kaplan–Meier methods, and factors associated with recurrence and mortality were examined using logistic and Cox regression. RESULTS Median survival from time of recurrence was 35 months in the patients with bone‐only metastases, compared with 11–26 months for all other sites of visceral recurrence exclusive of bone. Number of positive lymph nodes and estrogen receptor status were the only predictive variables for recurrence. Median survival from time of recurrence and time of original diagnosis for the 3 bone scan categories was: 1 lesion (n = 47), 53 and 86 months; 2 lesions (n = 22), 38 and 68 months; and ≥ 3 lesions (n = 44), 22 and 58 months (P < 0.0001 and P < 0.005 for 1 and 2 lesions vs. ≥ 3). In the “bone‐only” group, the number of scan lesions was the strongest predictor of length of survival. CONCLUSIONS Patients with breast carcinoma who experience a recurrence in bone at only one or two sites initially have a survival advantage over those with more extensive (≥ 3 sites) skeletal metastases and those with metastatic disease involving other visceral organs. Cancer 2001;91:17–24. © 2001 American Cancer Society.

show abstract

“…The same sentiment is echoed in the Invited Commentary by Karthikeyan and Park . If we look at the lead time gained by radiographic early detection, as shown in previously conducted studies, compared with symptomatic recurrence, it is around 6 months. A clinical lead time of more than 6 months was also seen in a randomized clinical trial comparing intensive vs clinical follow-up of patients with breast cancer after primary treatment .…”

mentioning

confidence: 78%

Clinical Benefit of Circulating Tumor DNA Analysis in Early-Stage Breast Cancer

2020

View full text Add to dashboard Cite

Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dislaimer:The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (https://acknowledgments.alliancefound.org).1. Basch E, Rogak LJ, Dueck AC. Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials.

show abstract

Selection of patients with breast cancer for routine follow-up bone scans

Cited by 14 publications

References 12 publications

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma

Clinical Benefit of Circulating Tumor DNA Analysis in Early-Stage Breast Cancer

Contact Info

Product

Resources

About